2024年12月30日 · AXS-05 is a fixed-dose combination of two approved drugs being developed for the treatment of agitation in people with Alzheimer’s disease. One component, …

Tools Ward K, Citrome L . AXS-05: an investigational treatment for Alzheimer's disease-associated agitation . Expert Opin Investig Drugs. 2022 Aug;31 (8):773-780. Epub 2022 Jul 6 …

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) . J Clin Psychiatry. 2022 May 30;83 …

2023年5月22日 · Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022 Jul;179 (7):490-499.

alpha-synuclein Amyloid-Related Cholesterol Cholinergic System Inflammation Metals Other Other Neurotransmitters Tau Unknown

Target Type All alpha-synuclein Amyloid-Related Cholesterol Cholinergic System Inflammation Metals Other Other Neurotransmitters Tau Unknown

2015年11月25日 · AD Target / Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics …

NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI …

Other compounds with sigma1R agonist activity are in clinical trials for Alzheimer's disease; they include blarcamesine, edonerpic, and the dextromethorphan formulations AVP-786, AVP-923, …

Network meta-analysis (NMA) of dextromethorphan-bupropion (AXS-05) efficacy and safety in major depressive disorder. Eur Neuropsychopharmacol. 2024 Sep;86:18-19.